UK Markets closed

Adocia SA (0QAI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.37-0.75 (-12.24%)
At close: 04:47PM BST
Full screen
Previous close6.12
Open5.37
Bid0.00 x 0
Ask0.00 x 0
Day's range5.37 - 5.37
52-week range5.37 - 5.37
Volume2,950
Avg. volumeN/A
Market cap37.452M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)-3.14
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    ADOCIA Announces its Annual Shareholders’ Meeting to Be Held on June 28, 2022 in Paris

    LYON, France, May 20, 2022--Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will hold its annual shareholders’ meeting ("AGM") on June 28, 2022, at 10.00 am at Hotel de Talleyrand, in the offices of Jones Day, 2 rue Saint Florentin, 75001 Paris.

  • Business Wire

    ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update

    LYON, France, May 18, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, reports today its first quarter financial results for 2022 and provides corporate update.

  • Business Wire

    ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao

    LYON, France, May 18, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the first subject treated in the BioChaperone® Combo ("BC Combo") CT046 clinical study.